Physician profile
Stuart C Pickell
NPI 1740261114
$3,365.56
in general payments reported to CMS, 2019-2025
29 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $86.23 · 2021: $29.54 · 2022: $1,021 · 2023: $848 · 2024: $488 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $505.87 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $394.42 | 2022-2023 | Freestyle Libre 2, Freestyle Libre |
| Lilly USA, LLC | $390.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $246.36 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $224.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Inspire Medical Systems, INC. | $208.76 | 2024-2025 | Inspire |
| Dexcom, INC. | $204.71 | 2022-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $175.36 | 2019-2024 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.93 | 2022-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $156.02 | 2019-2023 | |
| Pfizer INC. | $87.76 | 2019-2023 | |
| Eisai INC. | $70.99 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $70.09 | 2019-2022 | |
| Abbvie INC. | $61.20 | 2021-2023 | |
| Shire North American Group INC | $54.18 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $52.21 | 2020-2022 | |
| Medtronic, INC. | $37.19 | 2025 | Inceptiv |
| Exact Sciences Corporation | $35.73 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $33.31 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $28.95 | 2022-2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $24.77 | 2019 | |
| Philips North America LLC | $22.28 | 2024 | (Ck7) Extended Holter |
| Biohaven Pharmaceutical Holding Company LTD. | $21.80 | 2022 | |
| Allergan, INC. | $20.96 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.53 | 2022 | |
| Ibsa Pharma INC. | $16.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.60 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.15 | 2019 | |
| Astellas Pharma US INC | $12.94 | 2023 | Myrbetriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Pickell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.